Cross-over Study of Coronary Risk Factors With a Polypill

PHASE4RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 14, 2022

Primary Completion Date

March 30, 2026

Study Completion Date

April 30, 2026

Conditions

Coronary Artery Disease

Interventions

DRUG

Polypill of acetylsalicylic acid, ramipril and atorvastatin

Administration of acetylsalicylic acid, ramipril and atorvastatin in a polypill during 3 months more

DRUG

Drugs taken separately: acetylsalicylic acid, ramipril and atorvastatin

Patients will be receiving during 3 months more the same components acetylsalicylic acid, ramipril and atorvastatin than with the polypill

Trial Locations (1)

RECRUITING

Hospital Universitario de Cabueñes, Gijón

All Listed Sponsors

lead

Fundación EPIC

OTHER

NCT05030818 - Cross-over Study of Coronary Risk Factors With a Polypill | Biotech Hunter | Biotech Hunter